Breaking News

Financial Report: Alkermes

January 31, 2013

Revenues up 8% in the quarter


3Q Revenues: $135.9 million (+8%)

3Q Earnings: $16.3 million (loss of $14.8 million 3Q11)

YTD Revenues: $412.1 million (+59%)

YTD Earnings: $22.0 million (loss of $50.3 million YTD11)

Comments: Net sales of Vivitrol were $15.9 million, up 50%. Manufacturing and royalty revenues (M&R) were $118.3 million in the quarter, up 5%, and $364 million YTD, up 67%. Risperdal Consta and Invega Sustenna/Xeplion M&R revenues were $52.5 million in the quarter, up 10%. M&R revenues from Ampyra/Fampyra were $18.4 million, up 74%, and royalty revenues from Bydureon were $5.3 million, compared to $0.3 million in 3Q12. Other M&R revenues, which includes contract manufacturing operations, were $25.4 million in the quarter. R&D revenue was $1.7 million, down 24%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks